Drug · CHEMBL182
GANCICLOVIR
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GANCICLOVIR. Drugs and targets, record CHEMBL182. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL182
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- BW 759U, BW-759U, Gancyclovir, NSC-759656, RS-21592, Valganciclovir hydrochloride impurity a
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases37
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 37Source Open Targets
See all 37 diseasesTrials108
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02931539 | Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir | Phase 3 | 352 | 2021-09-23 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00497796 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients | Phase 3 | 307 | 2015-06-04 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00000134 | Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) | Phase 3 | 279 | 2015-09-14 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00000136 | Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) | Phase 3 | 234 | 2015-10-22 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT04706507 | Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis | Phase 3 | 205 | 2025-12-12 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT01335932 | Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure | Phase 2 | 160 | 2017-09-13 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00141037 | Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation | Phase 1/2 | 130 | 2013-07-11 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00000143 | Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) | Phase 3 | 61 | 2016-03-14 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | Phase 2 | 61 | 2017-12-02 | ganciclovir | Its name | ClinicalTrials.gov |
| NCT03586284 | Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes | Phase 2/3 | 51 | 2026-02-10 | ganciclovir | Its name | ClinicalTrials.gov |
1 to 10 of 108
See all 108 trialsComparisons in its trials24
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) vs Maribavir 400 mg: Number of Participants With All-cause Mortality by the End of the Study | 13 of 117 | 27 of 235 | 352 | NCT02931539 | Trial comparisons |
| Maribavir 100 mg BID vs Ganciclovir 1000 mg TID: Number of Participants Who Died Within 6 Months Post-Transplantation | 9 of 147 | 6 of 156 | 303 | NCT00497796 | Trial comparisons |
| Maribavir 100 mg BID vs Ganciclovir 1000 mg TID: serious adverse events | 71 of 147 | 76 of 156 | 303 | NCT00497796 | Trial comparisons |
| Foscarnet vs Ganciclovir: Mortality | 107 of 107 | 127 of 127 | 234 | NCT00000136 | Trial comparisons |
| Foscarnet vs Ganciclovir: serious adverse events | 60 of 107 | 73 of 127 | 234 | NCT00000136 | Trial comparisons |
| Maribavir 100 mg BID vs Ganciclovir 1000 mg TID: Number of Participants With EC-confirmed CMV Disease Within 100 Days Post-Transplantation | 10 of 113 | 0 of 120 | 233 | NCT00497796 | Trial comparisons |
| IV Ganciclovir vs Placebo: To Evaluate Whether Mortality and Time to Death in the 28 Days is Different Among Ganciclovir Recipients Relative to Placebo Recipients, Respectively. | 34 of 106 | 13 of 99 | 205 | NCT04706507 | Trial comparisons |
| IV Ganciclovir vs Placebo: To Evaluate Whether Mortality and Time to Death in the 180 Days is Different Among Ganciclovir Recipients Relative to Placebo Recipients, Respectively. | 45 of 106 | 22 of 99 | 205 | NCT04706507 | Trial comparisons |
| IV Ganciclovir vs Placebo: deaths from any cause | 45 of 106 | 22 of 99 | 205 | NCT04706507 | Trial comparisons |
| IV Ganciclovir vs Placebo: serious adverse events | 0 of 106 | 0 of 99 | 205 | NCT04706507 | Trial comparisons |
1 to 10 of 24
See all 24 comparisons in its trialsPapers from its trials50
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL182
GET https://conductscience.org/api/drugs/v1/CHEMBL182/diseases?page=2